APOA1/C3/A4/A5 and APOC3/A5 copy number losses were not associated with disease-free survival in patients with stage I–III breast cancer in NTUH discovery (Supplementary Fig. 5A) and validation cohorts (Supplementary Fig. 5B), respectively. Here, APOC3 is linked to breast cancer.